Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines. KU Leuven
Advanced stage ovarian cancer (OC) patients only have an overall 5-year survival of 20%. While targeted therapies such as PARP inhibitors have improved progression free survival, immunotherapy has so far not resulted in clear patient benefit. Importantly, the role of tumor-dendritic cells (DCs) as a key player in mounting an adaptive immune response has not been investigated yet in OC. Indeed, our lab has uncovered that vaccination with ...